Malignant Hyperthermia (MH)- New Insights and Connections with other Myopathies
Anesthesia and Analgesia article ” Future Directions in Malignant Hyperthermia Research and Patient Care” link to abstract.
Citation: Dirksen, SJH, Larach ML, Rosenberg H, Brandom BW, Parness J, Lang RS, Gangadharan M, Pezalski T. Future Directions in Malignant Hyperthermia Research and Patient Care. Anesth Analg June 27, 2011 ANE.0b013e318222af2e; published ahead of print June 27, 2011, doi:10.1213/ANE.0b013e318222af2e.
Conference Proceedings available early July. Please email your contact information to info@mhaus.org or call 607-674-7901 to receive notice of availability.
Order no-charge conference proceedings
Conference Objectives
- To discuss new advances in the pathophysiology of MH and to gain insight into the role of the skeletal muscle ryanodine receptor, type 1 (RYR1) and other genes in MH and other related disorders.
- To promote understanding of how MH susceptibility relates to other muscle disorders (e.g. Central Core Disease (CCD), muscular dystrophies, metabolic myopathies).
- To discuss advances in the genetics of MH and improvements in diagnosis for MH susceptibility.
- To improve the ability of anesthesiologists who volunteer as consultants (the HLCs) to provide up-to-date support to medical practitioners on the identification and management of MH and other muscle disorders.
- To introduce young anesthesiologists and other interested investigators to this area of medicine.
- This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of SUNY Upstate Medical University and the Malignant Hyperthermia Association of the United States (MHAUS). SUNY Upstate Medical University is accredited by the ACCME to provide continuing medical education for physicians.
- SUNY Upstate Medical University designates this educational activity for a maximum of 13.75 AMA PRA Category 1 Credit(s) (TM). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Please note:
Funding for this conference was made possible (in part) by an R13 Grant (1 R13AR05422-01) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), including co-funding from the Office of Rare Disease Research (ORDR). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
AGENDA Day 1- Friday, April 23, 2010
POSTERS SHOULD BE SET UP 7:00-8:00 AM
|
Time |
Topic |
Speaker(s) |
|
8:00-8:30 |
Welcome and Introductions |
Henry Rosenberg, MD, President, MHAUS Andrew Herlich, MD, UPMC and
|
|
Session 1 |
Pathophysiology of MH – Overview and Recent Advances in Understanding |
Session Chairperson: Jerome Parness, MD, PhD, UPMC |
|
8:30-9:00 |
Introduction to MH Pathophysiology; fresh approaches to understanding MH at cellular level; dantrolene & mechanism of action |
Jerome Parness, MD, PhD, UPMC |
|
9:00-9:45
|
Lessons from a Mouse Model of Malignant Hyperthermia: Mechanisms and New Interventions 9:45-10:00: Questions/Discussion |
Susan Hamilton, PhD , Baylor College of Medicine Keynote Speaker |
|
10:00-10:30
|
Mechanistic Models for the Cause of MH and for Core Formation in CCD 10:30-10:45 Questions/Discussion |
David MacLennan, PhD University of Toronto |
|
10:45-11:15 |
COFFEE BREAK |
|
|
11:15-11:45
|
11:45-12:00: Questions/Discussion |
Robert T. Dirksen, PhD University of Rochester |
|
12:00-12:30
|
Changes in DHPR kinetics induced by MH related conformational changes in RyR1 12:30-12:45: Questions/Discussion |
Paul Allen, MD, PhD Brigham and Women’s |
|
12:45-1:45 |
LUNCH |
|
|
Session 2 |
Genetics of MH: Results and Future Directions |
Chairperson: Sheila Muldoon, MD, USUHS |
|
1:45-2:15
|
|
Henrick Rueffert, MD University of Leipzig, Germany |
|
2:15-2:45
|
Reassessment of the operating characteristics of IVCT given genetic RYR1 results; update on the EMHG Reference: Improve on Phenotyping
|
Thierry Girard, MD University Hospital of Basel, Switzerland
|
|
2:45-3:15 |
Results of genetic testing (RYR1 gene findings) in basic research laboratories
|
Khishge Sambuughin, PhD, USUHS |
|
3:15-3:30 |
COFFEE BREAK
|
|
|
3:30-4:00 |
Assessment of RYR1 gene variants for Pathogenicity: Theory and Examples |
Jeffrey Kant, MD, PhD UPMC |
|
4:00-4:30 |
Results of genetic testing (RYR1 gene findings) in CLIA-approved clinical laboratories
|
Jim Weber, PhD Prevention Genetics |
|
4:30-5:15 |
Discussion of related questions
|
Sheila Muldoon, MD USUHS |
|
5:15-6:30 |
POSTER SESSION One, Two, Three, Four, Five, Six, Seven, Eight, Nine, Ten
|
AGENDA Day 2- Saturday, April 24, 2010
|
Time |
Topic |
Speaker(s) |
|
8:00-8:30 |
Welcome, Comment on Day 1
|
Sheila Muldoon, MD, USUHS |
|
Session 3 |
Relationship between MH-susceptibility and other muscle conditions/disorders |
Chairperson: Barbara Brandom, MD, UPMC |
|
8:30-8:45 |
Review of 2008 SPA Meeting Recommendations (anesthetic considerations in MH-associated diseases)
|
Barbara Brandom, MD UPMC |
|
8:45-9:15
|
Creatine Kinase and Heat Tolerance in Mice and Men 9:15-9:30: Questions/Discussion |
Patricia Deuster, PhD, MPH USUHS |
|
9:30-10:00 |
COFFEE BREAK |
|
|
10:00-10:30 |
Confounding Cases: Is this MH and How Would You Provide Anesthesia? 10:30-10:45: Questions/Discussion |
John Capacchione, MD USUHS |
|
10:45-11:15 |
Genetic susceptibility to statin-induced myopathy 11:15-11:30: Questions/Discussion |
Georgirene Vladutiu, PhD SUNY at Buffalo |
|
11:30-1:00 |
LUNCH & ADDITIONAL TIME TO VISIT POSTERS |
|
|
Session 4 |
MH Epidemiology
|
Chairperson: Henry Rosenberg, President, MHAUS |
|
1:00-1:15 |
Introduction to Epidemiology of MH; role of MH Hotline and North American MH Registry (NAMHR) databases as research and educational tools; implications and limitations of epidemiologic studies, Epidemiology Slide Handout |
Henry Rosenberg President, MHAUS |
|
1:15-1:45
|
1:45-2:00: Questions/Discussion |
Joanne E. Brady, SM, Columbia University |
|
2:00-2:45
|
Reference: Cardiac Arrests, Reference: Clinical Presentation 2:45-3:00: Questions/Discussion |
Marilyn Larach, MD Penn State College of Medicine |
|
3:00-3:15 |
COFFEE BREAK
|
|
|
Session 5
|
Future Directions/Challenges |
Chairperson: Henry Rosenberg, MD, President, MHAUS |
|
3:15-3:30 |
Changing Recommendations for Anesthesia Machine Preparation 3:30-3:45: Questions/Discussion |
David Rymer, MD UPMC
|
|
3:45-4:00 |
|
Barbara Brandom, MD UPMC |
|
4:00-4:30 |
|
Dale Micalizzi Board of Directors, MHAUS
|
|
4:30-5:00 |
Closing Remarks: Future directions for MH – research and non-invasive diagnostic testing; Future Directions for MHAUS –patient safety initiatives (ambulatory surgery issues, educational initiatives [simulation]); advice for MHS individuals. |
Henry Rosenberg, MD MHAUS |
